TARS Tarsus Pharmaceuticals Inc

0.21 (1.29%)
Last Updated: 11:29:22
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 36,833
Bid Price 16.57
Ask Price 16.62
News -
Day High 16.87


52 Week Range


Day Low 16.35
Company Name Stock Ticker Symbol Market Type
Tarsus Pharmaceuticals Inc TARS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.21 1.29% 16.55 11:29:22
Open Price Low Price High Price Close Price Prev Close
16.35 16.35 16.87 16.34
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
941 36,833 $ 16.68 $ 614,210 - 11.33 - 25.25
Last Trade Time Type Quantity Stock Price Currency
11:29:05 14 $ 16.59 USD

Tarsus Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
539.8M 32.62M - 25.82M -62.09M -1.90 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Tarsus Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No TARS Message Board. Create One! See More Posts on TARS Message Board See More Message Board Posts

Historical TARS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week16.6117.7215.8916.83348,701-0.06-0.36%
1 Month17.3117.7714.6116.34399,440-0.76-4.39%
3 Months17.3025.2514.6118.14470,105-0.75-4.34%
6 Months12.0525.2511.3317.47324,5954.5037.34%
1 Year15.9725.2511.3317.12203,9020.583.63%
3 Years18.3063.6910.800119.37122,526-1.75-9.56%
5 Years18.3063.6910.800119.37122,526-1.75-9.56%

Tarsus Pharmaceuticals Description

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.